RxDoctor Payments Data

Alison Robbins, NP

Nurse Practitioner · Macon, GANPI 1164862710

Payments from drug & device makers

$6,026in general payments, 2019–2025

Across 269 payments — averaging $22.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$1K
  • Sanofi$694
  • Boehringer Ingelheim$516
  • Insmed, Inc.$376
  • Grifols USA, LLC$284
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$5,82597%
  • Education$2013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,026 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$60,927
Medicare patients
424
Services billed
871

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter325$258,531
Prolastin CAlpha-1-Proteinase Inhibitor15$133,436
Breztri AerosphereBudesonide/Glycopyr/Formoterol149$102,211
Fasenra PenBenralizumab14$81,563
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr116$63,526
Breo ElliptaFluticasone/Vilanterol108$51,559
Stiolto RespimatTiotropium Br/Olodaterol Hcl51$39,388
SymbicortBudesonide/Formoterol Fumarate139$39,223
Ambrisentan13$37,050
Spiriva RespimatTiotropium Bromide72$36,953
Albuterol Sulfate HfaAlbuterol Sulfate739$19,855
EliquisApixaban28$16,274
Fluticasone-SalmeterolFluticasone Propion/Salmeterol89$11,937
Advair HfaFluticasone Propion/Salmeterol28$10,665
Spiriva HandihalerTiotropium Bromide12$5,914

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$1,141$377,980564 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,187$141,434288 claims
Grifols USA, LLCProlastin C$284$133,43615 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$516$76,341123 claims
PfizerEliquis$16$16,27428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →